---
title: "Policy Tailwinds Reshape Hong Kong's Forgotten Sectors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302401525.md"
description: "Policy adjustments in gas pricing, property curbs, and aviation are creating synchronized recovery signals across Hong Kong's niche sectors. China Resources Gas benefits from 52% of cities raising rates, while real estate firms adapt to eased restrictions and Meilan Airport capitalizes on record passenger traffic."
datetime: "2026-10-20T10:15:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302401525.md)
  - [en](https://longbridge.com/en/news/302401525.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302401525.md)
generator: "portal-rs"
---

# Policy Tailwinds Reshape Hong Kong's Forgotten Sectors

Hong Kong's overlooked sectors are finding new momentum through targeted policy shifts and operational pivots. China Resources Gas (1193.HK) has become the poster child for regulatory relief as 52% of Chinese prefectural cities adjust residential gas prices upward—a trend analysts expect to accelerate before winter heating season. The company's gas distribution segment now contributes 88.19% of revenue, reflecting strategic focus amid procurement cost stabilization.

Real estate players are navigating a turning point. Guangzhou and Shenzhen's removal of purchase restrictions and 15% down payment requirements have reversed six months of sales declines. Poly Real Estate (2777.HK) and Greentown China Holdings (9993.HK) are restructuring portfolios with hospitality segments now comprising nearly 20% of income, while Wing Tai Properties (0369.HK) explores asset-light models to weather the transition.

Hainan's aviation recovery is exceeding expectations. Meilan Airport (0357.HK) reported 7.9% year-on-year revenue growth in Q2 2024 as passenger traffic reached record levels. Its recent 10-year equipment leaseback deal provides liquidity for duty-free expansion, capitalizing on international flight restoration.

Innovation continues driving biotech potential. Laike Pharmaceuticals-B (2105.HK) advanced its AKT inhibitor LAE002 into Phase III trials for two cancer indications, with FDA-approved combination therapy protocols mirroring pathways that generated over $1 billion annually for comparable drugs.

Niche players are quietly adapting: Zhongwei New Materials (2579.HK) scales cathode production for EV batteries, Xinjaoyi Motorhome (0805.HK) monitors leisure travel demand shifts, HSBC-CSOP 70 US Treasury Bond ETF (3435.HK) offers dollar-denominated yield exposure, and Xunxiu Industrial (1962.HK) retools manufacturing lines for industrial recovery. These moves reflect a broader pattern—policy tailwinds are creating opportunities where fundamentals meet regulatory alignment.

### Related Stocks

- [01193.HK](https://longbridge.com/en/quote/01193.HK.md)
- [00357.HK](https://longbridge.com/en/quote/00357.HK.md)
- [02105.HK](https://longbridge.com/en/quote/02105.HK.md)
- [03435.HK](https://longbridge.com/en/quote/03435.HK.md)
- [02777.HK](https://longbridge.com/en/quote/02777.HK.md)
- [02579.HK](https://longbridge.com/en/quote/02579.HK.md)
- [01962.HK](https://longbridge.com/en/quote/01962.HK.md)
- [00369.HK](https://longbridge.com/en/quote/00369.HK.md)
- [09993.HK](https://longbridge.com/en/quote/09993.HK.md)
- [00805.HK](https://longbridge.com/en/quote/00805.HK.md)

## Related News & Research

- [Guangzhou R&F Bond Restructuring Plans Fail to Secure Required Creditor Support](https://longbridge.com/en/news/306246571.md)
- [Law Kiong Holdings Raises Stake in BLD Plantation to 6.816%](https://longbridge.com/en/news/305948439.md)
- [Laekna's Oral Obesity Drug LAE124 Reduces Body Weight in Rat Studies](https://longbridge.com/en/news/305249102.md)
- [Obesity Week 2026 | Laekna Announces Poster Presentation on LAE124, an Internally Discovered Oral Small-Molecule Amylin Receptor Agonist](https://longbridge.com/en/news/305249268.md)
- [CNGR Issues Further Announcement on DDL Transfer Valuation](https://longbridge.com/en/news/305353585.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**